Jan 2024 $26 M No. 5 $10 to $50 million 39
SPR Therapeutics, LLC: Raise no. 5, Jan 2024 × Investors in this round 39 investors had bought by the notice of Feb 5, 2024: 39 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $26 M of $26 M offered
Smallest investment taken no minimum stated
What was sold equity, other: Series D-1 Preferred Stock and the underlying Common Stock issuable upon its conversion Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Ben J. Austin · Executive Officer Josh J. Boggs · Executive Officer Maria E. Bennett · Executive Officer, Director Geoffrey B. Thrope · Director Michael J. Chuisano · Director Nicholas J. Valeriani · Director Robert B. Blankenship · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Ben Austin, Cfo. Source: SEC Form D, newest notice filed Feb 5, 2024. Read the notice at the SEC .
equity SEC Aug 2021 $20 M No. 4 $10 to $50 million 1
SPR Therapeutics, LLC: Raise no. 4, Aug 2021 × Investors in this round 1 investor had bought by the notice of Aug 31, 2021: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $20 M of $35 M offered; $15 M still to sell
Smallest investment taken no minimum stated
What was sold equity, other: Series D Preferred Stock and the underlying Common Stock issuable upon its conversion Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $1,200,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Ben J. Austin · Executive Officer Dave B. Youngberg · Executive Officer Josh E. Boggs · Executive Officer Maria E. Bennett · Executive Officer, Director Mark B. Stulz · Executive Officer Geoffrey B. Thrope · Director Michael E. Chuisano · Director Nicholas J. Valeriani · Director Robert B. Blankenship · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round SVB Leerink LLC (CRD 39011) · Boston, Massachusetts Sold in all US states Signed by Maria E. Bennett, President & CEO. Source: SEC Form D, newest notice filed Aug 31, 2021. Read the notice at the SEC .
equity SEC Jan 2019 $8 M No. 3 $2 to $10 million 1
SPR Therapeutics, LLC: Raise no. 3, Jan 2019 × Investors in this round 1 investor had bought by the notice of Jan 30, 2019: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $8 M of $20 M offered; $12 M still to sell
Smallest investment taken no minimum stated
What was sold equity, other: Series C-1 Preferred Stock and the underlying Common Stock issuable upon its conversion Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Ben J. Austin · Executive Officer Dave C. Youngberg · Executive Officer Josh C. Boggs · Executive Officer Maria E. Bennett · Executive Officer, Director Mark C. Stulz · Executive Officer Geoffrey B. Thrope · Director Les C. Vinney · Director Michael C. Chuisano · Director Nicholas J. Valeriani · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Maria E. Bennett, President & CEO. Source: SEC Form D, newest notice filed Jan 30, 2019. Read the notice at the SEC .
equity SEC Sep 2017 $15 M No. 2 $10 to $50 million 1
SPR Therapeutics, LLC: Raise no. 2, Sep 2017 × Investors in this round 1 investor had bought by the notice of Sep 21, 2017: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $15 M of $19 M offered; $4 M still to sell
Smallest investment taken no minimum stated
What was sold equity, other: Series C Preferred Stock and the underlying Common Stock issuable upon its conversion Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $900,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Dave C. Youngberg · Executive Officer Josh C. Boggs · Executive Officer Maria E. Bennett · Executive Officer, Director Mark C. Stulz · Executive Officer Geoffrey B. Thrope · Director Les C. Vinney · Director Michael C. Chuisano · Director Nicholas J. Valeriani · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Sword Securities LLC (CRD 32244) · Princeton, New Jersey Sold in CA, CO, MD, MN, NC, NJ, NY, OH, VT, WV Signed by Maria E. Bennett, President & CEO. Source: SEC Form D, newest notice filed Sep 21, 2017. Read the notice at the SEC .
equity SEC Oct 2011 $2 M No. 1 $2 to $10 million 17
SPR Therapeutics, LLC: Raise no. 1, Oct 2011 × Investors in this round 17 investors had bought by the notice of Jan 13, 2012: 17 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $2 M of $3 M offered; $0 M still to sell
Smallest investment taken $20,196
What was sold equity
Meant to last more than a year
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Limited Liability Company, incorporated in Ohio People named in the notice Geoffrey Thrope · Executive Officer, Director Maria Bennett · Executive Officer Len Cosentino · Director Les Vinney · Director Patricia Shrader · Director Ralph Della Ratta, Jr. · Director Warren Grill · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Anna L. Moscioni, Attorney-in-Fact under Power of Attorney dated 10/13/2011. Source: SEC Form D, newest notice filed Jan 13, 2012. Read the notice at the SEC .
equity SEC